Integradose Compounding Services Llc

What Integradose Compounding Services Llc does

Integradose Compounding Services LLC is a health-system-owned 503B outsourcing facility headquartered in Shoreview, Minnesota (Minneapolis metro), operating as a subsidiary of M Health Fairview. The company was carved out of Fairview Pharmacy to commercialize sterile compounded medications for hospital pharmacy departments and integrated health systems, targeting the operational pain points of drug shortages, supply unreliability, and the liability risk associated with in-house sterile compounding. Its customer base is concentrated in US hospitals, with a current geographic footprint centered on the Midwest.

The company operates a state-of-the-art compounding facility with five cleanrooms, an environmental monitoring program, and a sterile-to-sterile manufacturing process in which all components begin as sterile to eliminate contamination risk. Its commercial portfolio comprises nine products across opioid analgesics (fentanyl citrate, hydromorphone), epidural combinations (fentanyl with ropivacaine), obstetric (oxytocin), vasopressor (phenylephrine), and neuromuscular blockade reversal (sugammadex) categories, delivered in CADD cassettes, IV bags, and syringes with extended Beyond Use Dates of up to 180 days at room temperature. Each batch is tested for potency, sterility, and bacterial endotoxin via on-site and external labs before release, and the facility operates under 21 CFR Parts 210 & 211 and FDA 503B interim guidance.

The business model is direct, sales-led B2B distribution to hospital pharmacy buyers and health-system purchasing teams, with products fulfilled typically within one day. Commercial differentiators emphasized by the company include health-system provenance, no minimum-volume commitments, 'one price for all' transparent pricing, and anticipation-based compounding informed by patient volume patterns. The company is privately held with no external institutional capital, employs approximately 11 people, and has no public revenue disclosure.

Name

Integradose Compounding Services Llc

Legal name

IntegraDose Compounding Services LLC

Website

https://integradose.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Integradose is a health-system-owned 503B sterile compounding pharmacy in Shoreview, Minnesota, supplying hospital pharmacy departments with ready-to-use compounded medications including fentanyl, hydromorphone, oxytocin, phenylephrine, and sugammadex.

Ownership category

akta.pro rank

Product category

503B Sterile Compounding Pharmacy

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

Keywords

• 503B compounding pharmacy
• Sterile compounded medications
• Hospital pharmacy supply
• Outsourcing compounding facility
• Compounded sterile preparations

Headquarters

HQ city

Shoreview

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D

Revenue model

1. Compounded Pharmaceutical Products: Sale of sterile compounded medications to hospital pharmacy departments. Products include fentanyl citrate formulations, hydromorphone, oxytocin, phenylephrine hydrochloride, and sugammadex in various delivery formats (CADD cassettes, syringes, bags). Products are typically stable for months and offer extended beyond-use dates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IntegraDose is a 503B-registered sterile compounding pharmacy that manufactures and sells ready-to-use compounded pharmaceutical preparations (including fentanyl citrate, hydromorphone, oxytocin, phenylephrine, and sugammadex) to hospital pharmacy departments and health systems. Products are supplied in CADD cassettes, IV bags, and syringes with extended Beyond Use Dates, and are produced in a facility with five cleanrooms using a sterile-to-sterile manufacturing process with batch potency, sterility, and endotoxin testing.

Product overview

IntegraDose is a health system-owned 503B sterile compounding pharmacy that provides a portfolio of nine compounded pharmaceutical products designed for hospital use. The product line includes opioid analgesics (Fentanyl Citrate in various concentrations and presentations, Hydromorphone HCl), epidural analgesic combinations (Fentanyl with Ropivacaine), hormone formulations (Oxytocin in bag and syringe presentations), a vasopressor (Phenylephrine HCl), and a neuromuscular reversal agent (Sugammadex). All products are supplied in ready-to-use delivery formats including CADD cassettes, IV bags, and syringes, with extended Beyond Use Dates (BUDs) of up to 180 days at room temperature. The company compounds in anticipation of hospital needs and provides faster fulfillment (typically one day) compared to other 503B compounding pharmacies.

Differentiator

Problem solved

Functional benefit

Products and services

• Fentanyl Citrate 200 mcg/100 mL + 0.1% Ropivacaine in 0.9% Sodium Chloride (CADD cassette) Compounded sterile epidural analgesic combining fentanyl citrate with ropivacaine in a 0.9% Sodium Chloride solution, delivered via CADD cassette for hospital pain management. NDC: 71139-5340-4. Beyond Use Date of 120 days at room temperature.
• Fentanyl Citrate 2500 mcg/50 mL (CADD cassette) Compounded sterile concentrated fentanyl citrate formulation for injection via CADD pump, providing 50 mcg/mL concentration in a 50 mL reservoir cassette for hospital use. NDC: 71139-6030-1. Beyond Use Date of 180 days at room temperature.
• Fentanyl Citrate 400 mcg/200 mL + 0.1% Ropivacaine in 0.9% Sodium Chloride (IV bag) Compounded sterile higher-dose epidural analgesic combining fentanyl citrate with ropivacaine in 0.9% Sodium Chloride, supplied in a 200 mL IV bag for injection in hospital settings. NDC: 71139-5340-2.
• Hydromorphone HCl 20 mg/100 mL CADD for injection Compounded sterile opioid analgesic hydromorphone HCl for injection via CADD pump, delivering 0.2 mg/mL concentration in 0.9% Sodium Chloride for hospital pain management. NDC: 71139-0018-1.
• Oxytocin 30 Units in 0.9% Sodium Chloride (IV bag) Compounded sterile oxytocin formulation for injection delivered via IV bag with approximately 545 mL fill volume in a 500 mL bag of 0.9% Sodium Chloride, for hospital obstetric and surgical use. NDC: 71139-0012-1. Listed as a new product launching June 2026.
• Oxytocin 9 Units/9 mL Syringe in 0.9% Sodium Chloride Compounded sterile oxytocin syringe for injection delivering 1 Unit/mL concentration in a 12 mL syringe with 9 mL fill of 0.9% Sodium Chloride, for hospital obstetric use. NDC: 71139-0130-1. Beyond Use Date of 28 days at room temperature.
• Phenylephrine Hydrochloride 1000 mcg/10 mL in 0.9% Sodium Chloride (syringe) Compounded sterile vasopressor phenylephrine hydrochloride for injection delivering 100 mcg/mL concentration in a 12 mL syringe with 10 mL fill of 0.9% Sodium Chloride, for hospital vasopressor therapy. NDC: 71139-7084-2.
• Sugammadex 100 mg/1 mL (syringe) Compounded sterile neuromuscular reversal agent sugammadex for injection delivering 100 mg/mL concentration in a 3 mL syringe with 1 mL fill, for hospital anesthesia use. NDC: 71139-5355-2.
• Sugammadex 200 mg/2 mL (syringe) Compounded sterile neuromuscular reversal agent sugammadex for injection delivered in a 3 mL syringe with 2 mL fill, for hospital anesthesia use. NDC: 71139-5355-1.

Quantifiable outcome

• Products stable for months instead of mere hours
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Direct peers

• SCA Pharmaceuticals: SCA Pharmaceuticals is a 503B-registered outsourcing facility producing sterile admixtures and ready-to-administer injectable products for U.S. hospitals. It is a direct competitor in the same FDA Section 503B compounding category and overlaps with IntegraDose on anesthesia, pain, and perioperative sterile preparations.
• QuVa Pharma: QuVa Pharma is one of the largest 503B outsourcing compounders in the U.S., producing sterile injectable preparations for hospital and health-system pharmacies. It directly competes with IntegraDose in the same 503B regulatory category, hospital customer base, and sterile injectable product categories (analgesics, vasopressors, anesthesia drugs).
• Bayou City Labs: Bayou City Labs is a Texas-based FDA-registered 503B outsourcing facility producing sterile preparations for hospitals and health systems. It is a direct peer with comparable regulatory positioning and a focus on sterile injectable pharmacy products for institutional buyers.
• Leiters: Leiters is a 503B outsourcing sterile compounding pharmacy serving hospitals and health systems with ready-to-use preparations. It is a direct peer to IntegraDose, sharing the 503B regulatory model, sterile injectable focus, and hospital-pharmacy customer base.
• Olympia Pharmaceuticals: Olympia Pharmaceuticals is an FDA-registered 503B outsourcing facility producing sterile injectable preparations for hospitals and clinics. It is a direct peer to IntegraDose in the same outsourcing compounding category.
• Wells Pharmacy Network: Wells Pharmacy Network is a 503B-registered outsourcing compounding facility producing sterile preparations for hospital and clinic customers. It competes directly with IntegraDose in the same outsourcing segment and the same hospital buyer audience.

Broad incumbents

• Triad Sterile Compounding (now part of AmerisourceBergen / Cencora): AmerisourceBergen (now Cencora) acquired Triad Group's sterile compounding business, making it a broad incumbent distributor with its own 503B compounding capability. It competes with IntegraDose in sterile outsourcing but operates at far larger scale and as part of a national pharmaceutical distribution platform.
• PharMedium (Cencora / AmerisourceBergen): PharMedium was a 503B sterile compounding business integrated into Cencora (formerly AmerisourceBergen). As a broad incumbent with national distribution, it overlaps with IntegraDose's hospital compounding offering but at much greater scale and channel breadth.

Others

• M Health Fairview Pharmacy (parent operations): M Health Fairview is the parent health system that incubated IntegraDose and continues to operate an in-house pharmacy. It is not a direct competitor but is closely related as the originator and owner of IntegraDose and the reference customer for its products.

Emerging players

• Heritage Pharmaceuticals (sterile injectable franchise): Heritage Pharmaceuticals, part of the broader off-patent injectables space, produces sterile injectable products that overlap with IntegraDose's therapeutic categories (analgesics, vasopressors). It is an emerging/established player that competes for hospital pharmacy budgets through generic, rather than compounded, injectable products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/integradose-compounding-services-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integradose Compounding Services Llc